$20.22 Million in Sales Expected for Prothena Co. plc (NASDAQ:PRTA) This Quarter

Brokerages expect that Prothena Co. plc (NASDAQ:PRTAGet Rating) will report $20.22 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Prothena’s earnings. The lowest sales estimate is $230,000.00 and the highest is $40.20 million. Prothena reported sales of $160,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 12,537.5%. The firm is expected to announce its next quarterly earnings report after the market closes on Monday, January 1st.

On average, analysts expect that Prothena will report full year sales of $59.09 million for the current year, with estimates ranging from $40.68 million to $95.00 million. For the next fiscal year, analysts expect that the firm will post sales of $112.95 million, with estimates ranging from $75.90 million to $150.00 million. Zacks’ sales averages are an average based on a survey of analysts that follow Prothena.

Prothena (NASDAQ:PRTAGet Rating) last announced its earnings results on Thursday, February 17th. The biotechnology company reported ($0.71) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.03. Prothena had a net margin of 33.39% and a return on equity of 18.11%. The business had revenue of $1.17 million for the quarter, compared to the consensus estimate of $0.28 million. During the same quarter in the prior year, the firm posted ($0.77) earnings per share.

Several research firms recently commented on PRTA. StockNews.com began coverage on shares of Prothena in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Zacks Investment Research raised shares of Prothena from a “sell” rating to a “hold” rating and set a $35.00 price target on the stock in a research note on Wednesday, April 20th. Finally, Citigroup reduced their price target on shares of Prothena from $87.00 to $73.00 in a research note on Friday, February 18th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Prothena has a consensus rating of “Buy” and a consensus target price of $64.73.

Shares of PRTA opened at $31.26 on Thursday. Prothena has a twelve month low of $21.30 and a twelve month high of $79.75. The company has a market cap of $1.46 billion, a P/E ratio of 28.68 and a beta of 1.37. The company’s fifty day simple moving average is $34.71 and its 200-day simple moving average is $42.10.

In other Prothena news, Director Shane Cooke sold 5,000 shares of the stock in a transaction dated Monday, April 11th. The shares were sold at an average price of $35.08, for a total transaction of $175,400.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 31.20% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the company. Denali Advisors LLC bought a new stake in shares of Prothena in the 4th quarter valued at about $40,000. Allegheny Financial Group LTD bought a new stake in shares of Prothena in the 4th quarter valued at about $49,000. Spire Wealth Management boosted its stake in Prothena by 938.8% in the 4th quarter. Spire Wealth Management now owns 1,070 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 967 shares in the last quarter. Advisor Group Holdings Inc. boosted its stake in Prothena by 1,129.1% in the 3rd quarter. Advisor Group Holdings Inc. now owns 1,438 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 1,321 shares in the last quarter. Finally, Macquarie Group Ltd. acquired a new stake in Prothena in the 3rd quarter worth approximately $110,000. Institutional investors and hedge funds own 92.64% of the company’s stock.

Prothena Company Profile (Get Rating)

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

Recommended Stories

Get a free copy of the Zacks research report on Prothena (PRTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.